​​​​

1. Stereotactic Ablative Radiotherapy (SABR)

Indications:

Early-stage non-small cell lung cancer (NSCLC) in patients unsuitable for surgery.

Oligometastatic lung cancer for long-term disease control.

Expertise:

Accurate tumor targeting using advanced imaging modalities like 4D-CT, PET-CT, or MRI.

Planning and delivering high-dose precision radiation with minimal exposure to healthy tissues.

Managing potential SABR-related toxicities, such as radiation pneumonitis and rib fractures.

 

2. Chemotherapy

Indications:

Advanced-stage NSCLC and small cell lung cancer (SCLC).

Adjuvant or neoadjuvant treatment for resectable lung cancer.

Expertise:

Administration of platinum-based regimens (e.g., cisplatin or carboplatin with paclitaxel, gemcitabine, or pemetrexed).

Monitoring for and managing side effects such as neutropenia, nausea, and neuropathy.

Tailoring regimens for elderly or comorbid patients.

 

3. Tyrosine Kinase Inhibitors (TKIs)

Indications:

Targeted therapy for NSCLC with actionable mutations (e.g., EGFR, ALK, ROS1, MET, RET, or KRAS).

Expertise:

Prescribing and monitoring response to first-line and subsequent-line TKIs (e.g., osimertinib, alectinib, crizotinib).

Managing TKI-related side effects like skin rash, diarrhea, and hepatotoxicity.

Conducting molecular testing and integrating results into clinical decision-making.

 

4. Immunotherapy

Indications:

Advanced or metastatic NSCLC and SCLC without actionable mutations.

Maintenance therapy post-chemoradiation for unresectable stage III NSCLC.

Expertise:

Administering immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab, durvalumab, or atezolizumab).

Identifying and managing immune-related adverse events (e.g., colitis, pneumonitis, or endocrinopathies).

Monitoring patient response using RECIST criteria and imaging.

 

5. Radiotherapy (Conventional or Fractionated)

Indications:

Definitive treatment for locally advanced NSCLC or SCLC.

Palliation of symptoms such as hemoptysis or bone pain in metastatic lung cancer.

Expertise:

Design and delivery of fractionated radiotherapy schedules.

Advanced techniques, including intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT).

Managing radiation-induced side effects like esophagitis and lung fibrosis.

 

Additional Roles and Skills:

Multidisciplinary Team Collaboration: Active involvement in tumor boards for integrated patient care.

Clinical Trials: Participation in or leadership of trials evaluating new drugs or combination therapies for lung cancer.

Patient Support: Counseling patients about treatment options, prognosis, and supportive care strategies.

This extensive experience ensures a comprehensive and individualized approach to lung cancer management.